LNTH Stock Analysis: Lantheus Holdings | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 6.901m USD | 12M Return: 26.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 100M
EPS Trend: -24.4%
Qual. Beats: 2
Rev. Trend: 88.3%
Qual. Beats: 3
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Lantheus Holdings, Inc. is a Bedford, Massachusetts-based healthcare company founded in 1956 that develops, manufactures, and commercializes diagnostic and therapeutic products for heart, cancer, and other diseases. Operating in the radiopharmaceutical and medical imaging sector, the company serves clinicians worldwide with a portfolio centered on diagnostic imaging agents and emerging radiopharmaceutical therapies.
The commercial portfolio includes DEFINITY, an injectable ultrasound enhancing agent used in echocardiography; TechneLite, a technetium generator for nuclear medicine; Xenon-133 for pulmonary function assessment; Neurolite and Cardiolite for brain and cardiac imaging; and PYLARIFY, an F-18-labelled PSMA-targeted PET imaging agent for prostate cancer. The company also offers AI-driven software tools such as aPROMISE and PYLARIFY AI for quantitative medical imaging analysis.
Lantheus is advancing a development pipeline that includes PNT2002 and PNT2003 radiopharmaceutical therapies for metastatic castration-resistant prostate cancer and SSTR-positive neuroendocrine tumors, as well as imaging agents targeting Tau tangles in Alzheimers disease. The company maintains collaboration agreements with GE Healthcare, Curium Pharma, POINT, Regeneron, and Ratio Therapeutics, and trades on NASDAQ under the ticker LNTH following its 2015 IPO.
- PYLARIFY faces intensifying competition from Telixs Illuccix in PSMA imaging
- Pipeline therapies PNT2002 and PNT2003 advance in oncology radiopharmaceuticals
- DEFINITY ultrasound agent drives recurring revenue growth in core segment
| Net Income: 279.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA -7.06 > 1.0 |
| NWC/Revenue: 39.40% < 20% (prev 76.51%; Δ -37.12% < -1%) |
| CFO/TA 0.17 > 3% & CFO 407.7m > Net Income 279.0m |
| Net Debt (182.5m) to EBITDA (472.6m): 0.39 < 3 |
| Current Ratio: 2.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.8m) vs 12m ago -7.96% < -2% |
| Gross Margin: 60.48% > 18% (prev 64.04%; Δ -3.56% > 0.5%) |
| Asset Turnover: 70.25% > 50% (prev 74.77%; Δ -4.52% > 0%) |
| Interest Coverage Ratio: 19.86 > 6 (EBIT TTM 393.5m / Interest Expense TTM 19.8m) |
| A: 0.26 (Total Current Assets 942.3m - Total Current Liabilities 333.2m) / Total Assets 2.35b |
| B: 0.34 (Retained Earnings 797.9m / Total Assets 2.35b) |
| C: 0.18 (EBIT TTM 393.5m / Avg Total Assets 2.20b) |
| D: 1.07 (Book Value of Equity 1.21b / Total Liabilities 1.13b) |
| Altman-Z'' = 5.13 = AAA |
| DSRI: 1.01 (Receivables 355.7m/348.7m, Revenue 1.55b/1.54b) |
| GMI: 1.06 (GM 64.04% / 60.48%) |
| AQI: 2.42 (AQ_t 0.53 / AQ_t-1 0.22) |
| SGI: 1.01 (Revenue 1.55b / 1.54b) |
| TATA: -0.05 (NI 279.0m - CFO 407.7m) / TA 2.35b) |
| Beneish M = -2.12 (Cap -4..+1) = BB |
As of July 14, 2026, the stock is trading at USD 105.39 with a total of 1,025,734 shares traded. Over the past week, the price has changed by +2.50%, over one month by +0.69%, over three months by +29.04% and over the past year by +26.88%.
Current recommended Stop Loss: 100.80 (which is 4.4% or 1.2 ATR below the current price).
Lantheus Holdings has received a consensus analysts rating of 4.62. Therefore, it is recommended to buy LNTH.
- StrongBuy: 9
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 110.3 | 4.7% |
P/E Trailing = 25.4173
P/E Forward = 18.6916
P/S = 4.463
P/B = 5.6917
P/EG = 0.61
Revenue TTM = 1.55b USD
EBIT TTM = 393.5m USD
EBITDA TTM = 472.6m USD
Long Term Debt = 569.6m USD (from longTermDebt, last quarter)
Short Term Debt = 803k USD (from shortTermDebt, last quarter)
Debt = 681.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 55.3m
Net Debt = 182.5m USD (calculated: Debt 681.1m - CCE 498.6m)
Enterprise Value = 7.08b USD (6.90b + Debt 681.1m - CCE 498.6m)
Interest Coverage Ratio = 19.86 (Ebit TTM 393.5m / Interest Expense TTM 19.8m)
EV/FCF = 19.06x (Enterprise Value 7.08b / FCF TTM 371.7m)
FCF Yield = 5.25% (FCF TTM 371.7m / Enterprise Value 7.08b)
FCF Margin = 24.04% (FCF TTM 371.7m / Revenue TTM 1.55b)
Net Margin = 18.05% (Net Income TTM 279.0m / Revenue TTM 1.55b)
Gross Margin = 60.48% ((Revenue TTM 1.55b - Cost of Revenue TTM 611.0m) / Revenue TTM)
Gross Margin QoQ = 61.20% (prev 59.21%)
Tobins Q-Ratio = 3.02 (Enterprise Value 7.08b / Total Assets 2.35b)
Interest Expense / Debt = 2.91% (Interest Expense 19.8m / Debt 681.1m)
Taxrate = 25.33% (94.6m / 373.7m)
NOPAT = 293.8m (EBIT 393.5m * (1 - 25.33%))
Current Ratio = 2.83 (Total Current Assets 942.3m / Total Current Liabilities 333.2m)
Debt / Equity = 0.56 (Debt 681.1m / totalStockholderEquity, last quarter 1.21b)
Debt / EBITDA = 0.39 (Net Debt 182.5m / EBITDA 472.6m)
Debt / FCF = 0.49 (Net Debt 182.5m / FCF TTM 371.7m)
Total Stockholder Equity = 1.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.68% (Net Income 279.0m / Total Assets 2.35b)
RoE = 24.33% (Net Income TTM 279.0m / Total Stockholder Equity 1.15b)
RoCE = 22.92% (EBIT 393.5m / Capital Employed (Equity 1.15b + L.T.Debt 569.6m))
RoIC = 15.17% (NOPAT 293.8m / Invested Capital 1.94b)
WACC = 6.22% (E(6.90b)/V(7.58b) * Re(6.62%) + D(681.1m)/V(7.58b) * Rd(2.91%) * (1-Tc(0.25)))
Discount Rate = 6.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -69.38 | Cagr: -2.79%
[DCF] Terminal Value 73.10% ; FCFF base≈411.3m ; Y1≈360.7m ; Y5≈291.4m
[DCF] Fair Price = 69.04 (EV 4.68b - Net Debt 182.5m = Equity 4.49b / Shares 65.1m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -24.42 | EPS CAGR: -2.47% | SUE: 1.04 | # QB: 2
Revenue Correlation: 88.34 | Revenue CAGR: 11.24% | SUE: 1.44 | # QB: 3
EPS current Quarter (2026-06-30): EPS=1.31 | Chg30d=+0.49% | Revisions=+8% | Analysts=11
EPS next Quarter (2026-09-30): EPS=1.30 | Chg30d=+0.42% | Revisions=-50% | Analysts=11
EPS current Year (2026-12-31): EPS=5.38 | Chg30d=+0.96% | Revisions=+80% | GrowthEPS=-11.4% | GrowthRev=-4.6%
EPS next Year (2027-12-31): EPS=6.37 | Chg30d=-0.38% | Revisions=+0% | GrowthEPS=+18.4% | GrowthRev=+13.3%
[Analyst] Revisions Ratio: +16% (up=20, down=14)